Wall Street analysts are increasingly optimistic about Texas Instruments (NASDAQ:TXN) following the company’s recent capital management call, where it outlined promising cash flow targets and flexible capital expenditure (CapEx) plans for the future.
This renewed confidence is reflected in recent notes from UBS, Evercore ISI, and Citi following the call, with each highlighting different aspects of TXN’s potential growth and financial health.
UBS praised Texas Instruments for addressing CapEx flexibility in 2026 and beyond, noting that the company is positioned to reclaim its pre-COVID analog market share.
Analysts see this as a key driver for growth, estimating that each 100 basis points of market share recovery could boost growth by 5 to 6 percentage points.
The firm also highlighted TXN's unique competitive advantage in China, where it remains one of the few analog companies capable of competing effectively due to its cost position. UBS has adjusted its free cash flow (FCF) estimates slightly upward and maintained a price target of $250 and a Buy rating on the stock.
Evercore ISI reiterated its Outperform rating on TXN, emphasizing that the company's free cash flow growth story is playing out as expected.
The firm pointed to several factors that make TXN a top pick in the analog semiconductor space, including the expected expansion of FCF per share from $1 to $11 between March 2024 and December 2026. Evercore has a price target of $268 on the stock, citing significant upside potential based on TXN's historical trading multiples.
Citi upgraded TXN to a Buy rating, raising its price target from $200 to $235. The upgrade comes after TXN lowered its 2026 CapEx estimates and indicated that gross margins are likely bottoming.
Analysts believe this could lead to a substantial rebound in earnings, projecting a 100% increase in EPS.
Overall, analysts are becoming increasingly bullish on Texas Instruments, seeing substantial upside in its cash flow, market share recovery, and profitability.